Clinical Trials Search at Vanderbilt-Ingram Cancer Center

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab)
taken alone or together with standard chemotherapy for the potential treatment of colorectal
cancer that:

- has spread to other parts of the body (metastatic);

- has a certain type of abnormal gene called "BRAF"; and

- has not received prior treatment.

Participants in this study will receive one of the following study treatments:

- Encorafenib plus cetuximab: These participants will receive encorafenib by mouth at home
every day and cetuximab once every two weeks by intravenous (IV) infusion (an injection
into the vein) at the study clinic.

- Encorafenib plus cetuximab with chemotherapy: These participants will receive
encorafenib and cetuximab in the way described in the bullet above. Additionally, they
will receive standard chemotherapy by IV infusion and oral treatment at home.

- Chemotherapy alone: These participants will receive chemotherapy, the standard treatment
for this condition, by IV infusion at the study clinics and oral treatment at home.

The study team will monitor how each participant responds to the study treatment for up to
about 3 years.

This is a three-part study of NUC-3373 administered by intravenous (IV) infusion across two
administration schedules, either as monotherapy or as part of various combinations with
agents commonly used to treat CRC (leucovorin, oxaliplatin, irinotecan, bevacizumab,
cetuximab and panitumumab). The primary objective is to identify a recommended dose and
schedule for NUC-3373 when combined with these agents.

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's
Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous
Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of
Therapy

The purpose of this study is to find out whether the study drug, LY3537982, is safe and
effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must
have already received or were not able to tolerate the standard of care. The study will last
up to approximately 2 years.

TTX-080-01 is a Phase 1, open label, dose escalation and dose expansion clinical study to
determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy
(HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab
(EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies.

The study is enrolling in the dose expansion cohorts.